GAITHERSBURG, Md. , April 09, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX) today announced that Gregory M. Glenn , M.D., President of Research and Development, will share data from its global Phase 3 clinical trial of ResVax™, the respiratory syncytial virus (RSV) fusion (F) protein...More>>

Company to Host Conference Call Today at 4:30 p.m. ET GAITHERSBURG, Md. , March 18, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the fourth quarter and twelve months ended December 31, 2018 ....More>>

GAITHERSBURG, Md. , March 11, 2019 (GLOBE NEWSWIRE) --Novavax, Inc. (Nasdaq: NVAX) today announced it will report its fourth quarter and year-end 2018 financial and operating results following the close of U.S. financial markets on Monday, March 18, 2019....More>>

Trial did not meet primary objective of prevention of medically significant RSV LRTI Trial did show efficacy against secondary objective (RSV LRTI hospitalization); first RSV vaccine to show Phase 3 efficacy Other pre-specified exploratory endpoints and post-hoc analyses highlight potential to...More>>

Sets the Stage for Phase 3 Clinical Trial in 2019 Phase 2 clinical trial confirmed Phase 1/2 results, again demonstrating improved immune responses over Fluzone ® High-Dose End-of-Phase 2 meeting with the FDA expected in the first half of 2019 Pivotal Phase 3 clinical trial expected to initiate in...More>>

GAITHERSBURG, Md. , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced that it will present at the 37th Annual J.P. Morgan Healthcare Conference . Presentation details are as follows: Date and time: Wednesday, January 9 , 3:00 p.m. – 3:25 p.m. P.T....More>>